[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ivf-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ivf-outcomes":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,75,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100628035","development-of-an-ai-platform-for-the-analysis-of-sperm-and-prediction-of-their-clinical-potential-100628035",false,"NCT07456397","Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential","Development and Validation of an Artificial Intelligence Platform for the Analysis of Sperm Samples and Prediction of Their Clinical Potential","Spermy01","Male participants:\n\nInclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n* Semen sample intended for use in an IVF\u002FICSI cycle\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months\n\nFemale participants:\n\nInclusion Criteria:\n\n* Urdengoing an IVF\u002FICSI cycle with partner or donor semen\n\nExclusion Criteria:\n\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","ALL","18 Years","60 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to develop an artificial intelligence platform for the analysis of sperm samples and prediction of their clinical potential, in 500 semen samples, in an in vitro study over 24 months.",[26,27,28,29,30],"Infertility (IVF Patients)","ICSI","IVF Outcomes","Male Infertility","Reproductive Issues","RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2026-03-18",{"date":39,"type":22},"2028-02",{"name":41,"class":42},"Fecundis Lab SL","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100625626","helios-advanced-human-oocyte-illumination-to-enhance-development-100625626","NCT07425080","HELIOS Advanced: Human Oocyte Illumination to Enhance Development","HELIOS-Advanced: A Prospective, Staged Dose-Escalation Study of Photobiomodulation to Improve Embryo Development in In Vitro Fertilization","HELIOS-A","Inclusion Criteria:\n\n* Female age between 18-48 years at the time of the IVF\u002FICSI cycle\n* Undergoing blastocyst culture\n* Using own oocytes\n* Has at least two oocytes available for randomization\n* Consenting to oocyte level randomization\n* Plan to transfer euploid embryo within 6 months\n\nExclusion Criteria:\n\n* Use of donor oocytes or gestational carrier\n* Concurrent experimental laboratory inventions outside of protocol\n* Refusal of randomization or request for non-standard handling",true,"FEMALE","48 Years",{"count":55,"type":22},270,"INTERVENTIONAL",[58],"NA","Oocytes need a lot of energy to complete meiosis and fertilize successfully. As women get older, the \"power plants\" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.",[28],[62,63,64],"Infertility","Embryo arrest","Fertility","2026-03-23",{"date":67,"type":35},"2026-03-25",{"date":69,"type":22},"2026-03-24",{"date":71,"type":22},"2028-06-01",{"name":73,"class":42},"Columbia University",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100601422","ovarian-stimulation-outcomes-during-a-gnrh-antagonist-protocol-for-in-vitro-fertilization-when-comparing-trigger-day-decision-by-physicians-versus-an-artificial-intelligence-based-algorithm-100601422","NCT07110285","Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm.","Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm - A Randomized Control Study.","Inclusion Criteria:\n\n* All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed).\n\nExclusion Criteria:\n\n* Loss to follow-up, patient retracts consent to participate","45 Years",{"count":84,"type":22},180,[58],"To compare the number of mature oocytes following a GnRH antagonist in-vitro fertilization stimulation cycle when comparing trigger day timing decision by physicians versus an artificial intelligence-based algorithm",[28],[89,90,91,92],"Trigger day decision","In-vitro fertilization","Mature oocytes","Artifical intelligence-based algorithm","2026-01-08",{"date":95,"type":35},"2026-01-12",{"date":97,"type":35},"2025-05-21",{"date":99,"type":22},"2028-05-21",{"name":101,"class":102},"FertilAI","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":52,"minAge":111,"maxAge":82,"enrollmentInfo":112,"targetDuration":4,"studyType":56,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100577111","the-effect-of-vitc-on-ivf-outcome-of-dor-patients-100577111","NCT06794047","The Effect of VitC on IVF Outcome of DOR Patients","The Effect of Vitamin C Supplementation on Assisted Reproductive Pregnancy Outcomes in Patients With Diminished Ovarian Reserve: A Multicenter, Double-blind, Randomized Controlled Trial.","DORIVF-VC","Definition of DOR: Currently, there is no internationally unified standard for DOR. According to the latest POSEIDON criteria for diminished ovarian reserve (DOR), serum AMH \\\u003C1.20 ng\u002FmL or bilateral antral follicle count (AFC) \\\u003C5 is classified as DOR.\n\nIn this study, the participants are primarily DOR patients, with the following inclusion criteria:\n\n* Infertile women undergoing their 1st or 2nd IVF treatment\n* Diagnosed with DOR: POSEIDON criteria (AMH \\\u003C1.2 ng\u002FmL or bilateral AFC \\\u003C5) BMI between 18.5-28.0 kg\u002Fm²\n* Signed informed consent\n\nExclusion Criteria：Participants meeting any of the following criteria will be excluded from the trial:\n\n* PGT (preimplantation genetic testing) candidates\n* DOR caused by ovarian surgery, cancer radiotherapy\u002Fchemotherapy\n* Other ovulation disorders (e.g., PCOS, Cushing's syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia) or endometriosis (chocolate cysts)\n* Severe thyroid disorders: Hyperthyroidism, Graves' disease, Hashimoto's thyroiditis\n* Acute\u002Fchronic renal insufficiency, hemodialysis, or history of severe kidney impairment\n* Infectious diseases: HIV, active hepatitis, metabolic acidosis, tuberculosis, etc.\n* Severe autoimmune diseases (e.g., rheumatoid arthritis, lupus, Crohn's disease)\n* Cardiovascular events within the past 3 months: Coronary artery disease\u002Fmyocardial infarction\u002Fclinically significant congestive heart failure；Stroke\u002Ftransient ischemic attack (TIA)；Deep vein thrombosis\u002Fpulmonary embolism；Poorly controlled hypertension (SBP ≥160 mmHg or DBP ≥90 mmHg)；Diagnosed diabetes mellitus；Coronary intervention (PCI) or coronary artery bypass grafting (CABG)；\n* Neurological disorders (e.g., dementia,Alzheimer's, Parkinson's) or use of related medications\n* Psychiatric disorders or use of antiepileptic\u002Fantidepressant drugs\n* History of cancer or radiotherapy\u002Fchemotherapy\n* Allergy to vitamin C\n* Current high-dose vitamin C supplementation (\\>500 mg\u002Fday)\n* Unwillingness to take the study-provided supplements\n* Alcohol abuse, smoking, or drug addiction\n* Participation in other clinical trials within the past month","20 Years",{"count":113,"type":22},1100,[58],"In the context of the accelerating aging population and the continuous decline in birth rates nationwide, delaying reproductive aging in women and protecting the fertility of women of childbearing age have become urgent issues and key demands that need to be addressed in the field of maternal and child health in China. The ovaries have reproductive and hormone secretion functions and are crucial throughout the female reproductive lifecycle. Women of childbearing age in China face a serious problem of diminished ovarian reserve (DOR), which can lead to infertility, failed in vitro fertilization (IVF) treatments, miscarriage, and other adverse pregnancy outcomes, severely affecting the safety of women and their offspring. For DOR patients who desire to conceive, failure to intervene and treat promptly can result in irreversible losses and impose a significant psychological burden on them. However, there are currently no clear and reliable interventions that can improve ovarian function and enhance fertility in women with DOR. Therefore, exploring new, safe, and patient-acceptable intervention strategies is urgently needed, as it may bring hope and light to women with DOR. Nutrient supplementation, especially vitamin supplementation, has received increasing attention in disease treatment due to its safety, bioavailability, and effectiveness. Previous studies have shown that vitamin C may play an important role in treating diminished ovarian reserve. However, its effects on ovarian function need to be validated in the population.\n\nBased on the above research background, this project will conduct a randomized, placebo-controlled, double-blind, multicenter trial. The study subjects will be DOR infertility patients undergoing IVF\u002FICSI treatment. The intervention group will receive oral vitamin C supplementation at a dosage of 500 mg per dose, twice a day; the control group will receive a placebo with the same dosage and method for at least three months. Patients will be followed up until delivery outcomes, comparing the IVF\u002FICSI treatment results between the vitamin C supplementation group and the placebo group. The primary endpoint of this clinical trial is the live birth rate of the IVF\u002FICSI treatment cycle. Secondary endpoints include indicators of improved ovarian reserve function, ovarian aging molecular clocks, IVF-embryo culture indicators, pregnancy rates, pregnancy complications, and neonatal conditions, thereby providing new clues and theoretical basis for clinical treatment plans for DOR patients.",[117,28],"Diminished Ovarian Reserve",[119,120,121,122],"vitamin C","IVF outcomes","livebirth","diminished ovarian reserve","2025-06-11",{"date":125,"type":35},"2025-06-17",{"date":127,"type":35},"2025-03-17",{"date":129,"type":22},"2027-12-31",{"name":131,"class":42},"Peking University Third Hospital",6,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":56,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100593202","comparison-of-two-protocols-in-frozen-embryo-transfer-100593202","NCT07003373","Comparison of Two Protocols in Frozen Embryo Transfer","Comparison of the Pregnancy Outcomes of Frozen Embryo Transfer in the Natural Cycle vs. Artificial Cycle","Inclusion Criteria:\n\nRegular menstrual cycles\n\nMaternal age between 18 and 42 years\n\nNormal intrauterine cavity confirmed by pretreatment ultrasound or hysteroscopy\n\nBody Mass Index (BMI) less than 30 kg\u002Fm²\n\nNo ovulation disorders\n\nExclusion Criteria:\n\nNo embryos available for transfer (no embryo thawing)\n\nWithdrawal of patient consent to continue treatment\n\nFailure of dominant follicle development (in natural cycle group)\n\nInadequate endometrial response for transfer\n\nNo endometriosis grade 3 or higher\n\nThe participant provided written informed consent","42 Years",{"count":142,"type":22},112,[58],"This randomized clinical trial evaluates two different endometrial preparation protocols-hormone replacement therapy (HRT) and natural cycle-for frozen embryo transfer (FET) in infertile women undergoing assisted reproductive technology (ART). The goal is to compare implantation, clinical pregnancy, and ongoing pregnancy outcomes.",[28],[147,148,149],"Natural cycle","Artificial cycle","Frozen embryo transfer","NOT_YET_RECRUITING","2025-05-25",{"date":153,"type":35},"2025-06-04",{"date":155,"type":22},"2025-07-05",{"date":157,"type":22},"2026-07-05",{"name":159,"class":42},"Malihe Mahmoudinia"]